Reflux Drugs: Medications That Cause or Treat Acid Reflux

Why Reflux Happens: The Lower Esophageal Sphincter Problem

Reflux occurs when gastric contents move backward through the lower esophageal sphincter (LES) into the esophagus. The LES is a 3-4 cm zone of tonically contracted smooth muscle that normally maintains a resting pressure of 10-30 mmHg above intragastric pressure. When that pressure drops below a functional threshold, acid and pepsin contact the esophageal mucosa and produce the burning, regurgitation, and chest discomfort that define gastroesophageal reflux disease (GERD).

The American College of Gastroenterology (ACG) 2022 clinical guideline defines GERD as "symptoms or complications resulting from the reflux of gastric contents into the esophagus or beyond" [1]. Three mechanisms drive most episodes: transient LES relaxations (TLESRs) that occur independently of swallowing, a chronically hypotensive LES, and anatomic disruption from a hiatal hernia. Drugs affect all three pathways. Some medications lower LES tone directly through smooth-muscle relaxation. Others slow gastric emptying, increase gastric volume, or injure mucosal tissue on contact. Understanding these pharmacologic triggers is the first step toward separating treatable GERD from drug-induced reflux that may resolve with a simple medication change [2].

The prevalence is not trivial. A 2020 systematic review in Gut estimated weekly GERD symptoms in 13.3% of the global population, with North American prevalence near 19.8% [3]. That overlap between a common condition and commonly prescribed medications makes drug-induced reflux an underdiagnosed contributor.

Proton Pump Inhibitors: The Gold Standard Treatment

PPIs are the most prescribed drug class for GERD worldwide, and the data supports that position. They irreversibly inhibit the hydrogen-potassium ATPase enzyme on the parietal cell, blocking the final step of acid secretion regardless of the upstream stimulus.

An 8-week course of standard-dose PPI heals erosive esophagitis in 85-96% of patients compared to 50-60% for H2 receptor antagonists, according to a Cochrane meta-analysis of 134 trials (N=36,978) [4]. The six available PPIs (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole) show broadly similar efficacy at equivalent doses, though esomeprazole 40 mg demonstrated a small but statistically significant healing advantage over omeprazole 20 mg in the EXPO study (93.7% vs. 84.2% at 8 weeks, P<0.001) [5].

Timing matters more than brand selection. PPIs require an acidic environment plus actively secreting proton pumps to bind their target. The ACG guideline recommends dosing 30-60 minutes before the first meal of the day [1]. Patients who take PPIs at bedtime or without food often report poor symptom control, and simply correcting administration timing resolves symptoms in up to 20% of apparent PPI non-responders.

Standard PPI dosing for GERD treatment:

• Omeprazole: 20 mg once daily (healing dose: 20-40 mg)
• Esomeprazole: 20-40 mg once daily
• Lansoprazole: 30 mg once daily
• Pantoprazole: 40 mg once daily
• Rabeprazole: 20 mg once daily
• Dexlansoprazole: 30-60 mg once daily (dual-release, no meal timing requirement)

Long-term PPI safety has drawn scrutiny. A 2019 randomized trial in Gastroenterology (N=17,598) found no significant increase in adverse events over 3 years of pantoprazole 40 mg daily versus placebo, though observational studies have flagged associations with C. difficile infection, chronic kidney disease, and hypomagnesemia at rates that remain low in absolute terms [6]. The FDA recommends using the lowest effective dose for the shortest duration necessary, particularly when prescribing beyond 8 weeks.

H2 Receptor Antagonists: Second-Line and Nighttime Options

Famotidine is now the primary H2 receptor antagonist (H2RA) available in the U.S. after the FDA's 2020 withdrawal of ranitidine due to N-nitrosodimethylamine (NDMA) contamination concerns [7]. H2RAs competitively block histamine at the parietal cell, reducing basal and meal-stimulated acid secretion by 50-70%, a meaningful but smaller reduction than PPIs achieve.

Their role is specific rather than general. Famotidine 20 mg twice daily works well for patients with mild, intermittent symptoms or as an on-demand option. It also fills a niche for nocturnal acid breakthrough, a pattern where symptoms return overnight despite morning PPI dosing. Adding famotidine 20 mg at bedtime to a PPI regimen reduced nocturnal esophageal acid exposure from 36% to 5.3% of the sleep period in a crossover study (N=20) published in the American Journal of Gastroenterology [8].

One limitation is tachyphylaxis. Tolerance to H2RAs develops within 2-6 weeks of continuous use, reducing their nighttime acid suppression by roughly 50% compared to initial dosing. For this reason, the ACG suggests using nighttime H2RAs intermittently rather than as a fixed daily addition [1].

Potassium-Competitive Acid Blockers: A Newer Mechanism

Vonoprazan, approved by the FDA in 2023 as part of Voquezna Triple Pak and Voquezna Dual Pak for H. pylori eradication, represents a distinct pharmacologic approach. Unlike PPIs, potassium-competitive acid blockers (P-CABs) inhibit the proton pump competitively and reversibly, achieving near-complete acid suppression within hours of the first dose rather than the 3-5 days PPIs require to reach steady state [9].

In erosive esophagitis, a phase 3 trial (N=1,024) published in Clinical Gastroenterology and Hepatology found vonoprazan 20 mg noninferior to lansoprazole 30 mg for 8-week healing rates (93% vs. 90%, respectively) [10]. The speed of onset makes P-CABs potentially useful for patients who need rapid symptom control. Vonoprazan does not require pre-meal timing because it does not depend on active acid secretion to bind its target. This removes the adherence barrier that undercuts PPI effectiveness in real-world use.

Drugs That Cause Reflux: A Systematic Review of Offenders

Drug-induced reflux is more common than most patients realize. A 2014 review in Alimentary Pharmacology and Therapeutics identified over 15 drug classes associated with GERD symptoms through three primary mechanisms: LES relaxation, direct mucosal injury, and delayed gastric emptying [11].

Calcium Channel Blockers

Nifedipine, amlodipine, and diltiazem relax smooth muscle throughout the body, including the LES. Manometric studies show nifedipine reduces LES pressure by 30-50% within 30 minutes of oral dosing [12]. A case-control study published in the BMJ (N=7,159) found patients on calcium channel blockers had an adjusted odds ratio of 1.73 (95% CI 1.14-2.64) for GERD symptoms compared to non-users [13]. Amlodipine, the most widely prescribed calcium channel blocker in the U.S., has a longer half-life (30-50 hours) than nifedipine, which means its LES-relaxing effect persists around the clock.

For patients who develop reflux on a calcium channel blocker, switching to an ACE inhibitor or ARB for blood pressure control often resolves GERD symptoms without adding a PPI.

NSAIDs and Aspirin

Ibuprofen, naproxen, and aspirin damage the esophageal mucosa through direct topical injury and systemic COX-1 inhibition, which reduces protective prostaglandin synthesis. A population-based cohort in Gut (N=49,798) demonstrated that regular NSAID users had double the risk of erosive esophagitis compared to non-users (relative risk 2.11, 95% CI 1.73-2.58) [14]. Low-dose aspirin (75-325 mg daily) carries a lower but still measurable risk, particularly when combined with other refluxogenic drugs.

The protective strategy is straightforward: co-prescribe a PPI when chronic NSAID use is necessary. The VENUS and PLUTO trials (combined N=1,429) showed esomeprazole 20 mg daily reduced the 6-month rate of peptic ulcers and erosive esophagitis by 75-80% in NSAID users [15].

Bisphosphonates

Alendronate and risedronate, taken orally for osteoporosis, can cause pill esophagitis, a localized mucosal burn where the tablet lodges against the esophageal wall. The FDA labeling for alendronate includes a black-box-adjacent warning to take the tablet with a full glass of water, remain upright for 30 minutes, and avoid lying down after dosing. Patients with pre-existing GERD or esophageal motility disorders face the highest risk. Switching to intravenous zoledronic acid (5 mg once yearly) or subcutaneous denosumab eliminates esophageal exposure entirely [16].

Benzodiazepines and Anticholinergics

Diazepam, alprazolam, and other benzodiazepines reduce LES pressure through central and peripheral smooth-muscle relaxation. Anticholinergic medications (oxybutynin, dicyclomine, diphenhydramine, first-generation antihistamines) reduce LES tone and simultaneously slow gastric motility, increasing the volume of gastric contents available for reflux. Dr. Peter Kahrilas, a gastroenterologist at Northwestern University Feinberg School of Medicine, noted in a 2020 review: "The anticholinergic burden of a patient's medication list is one of the most overlooked modifiable risk factors for refractory GERD" [17].

Other Drug Classes Linked to Reflux

• Nitrates (isosorbide mononitrate, nitroglycerin): potent LES relaxants
• Theophylline: directly relaxes LES smooth muscle and stimulates acid secretion
• Progesterone and combined oral contraceptives: explain the increased reflux prevalence during pregnancy and in women on hormonal therapy
• Opioids: delay gastric emptying significantly, increasing reflux volume
• Selective serotonin reuptake inhibitors (SSRIs): modest association through effects on esophageal motility
• Iron supplements: direct mucosal irritation, particularly with ferrous sulfate

How to Diagnose Whether Your Reflux Is Drug-Induced

The differential between idiopathic GERD and drug-induced reflux follows a clear clinical sequence. Step one is a thorough medication reconciliation. Step two is a temporal correlation: did symptoms start or worsen within days to weeks of initiating a new drug or increasing a dose?

The ACG 2022 guideline recommends a PPI trial of 8 weeks as the initial diagnostic and therapeutic test for typical GERD symptoms (heartburn and regurgitation) before pursuing endoscopy or pH testing [1]. If a patient's symptom onset correlates with a new medication, a supervised discontinuation or substitution trial is reasonable before escalating to endoscopy. When the offending drug is stopped and symptoms resolve within 2-4 weeks, the diagnosis is confirmed retrospectively.

Ambulatory pH monitoring (Bravo wireless capsule or impedance-pH catheter) is the gold standard for quantifying reflux. A DeMeester score above 14.7 or acid exposure time exceeding 6% over 24 hours confirms pathologic reflux [18]. These tests become necessary when empiric PPI therapy fails, when surgical referral is considered, or when the diagnosis remains unclear after medication adjustment.

Upper endoscopy (EGD) is indicated for alarm features: dysphagia, odynophagia, unintentional weight loss, gastrointestinal bleeding, or persistent symptoms despite 8 weeks of optimized PPI therapy. The Los Angeles classification grades erosive esophagitis from A (mucosal breaks <5 mm) through D (circumferential mucosal breaks), and the grade guides treatment duration and follow-up intervals [1].

Stepping Down and Deprescribing: When to Stop GERD Medications

Not every patient needs indefinite acid suppression. The ACG recommends attempting PPI step-down in patients with non-erosive reflux disease (NERD) after an initial 8-week course [1]. Strategies include switching to on-demand PPI use, stepping down to half-dose, or transitioning to famotidine.

Dr. Kenneth DeVault, former ACG president, stated in the 2022 guideline update: "Maintenance PPI therapy is appropriate for patients with erosive esophagitis grade C or D, Barrett's esophagus, or peptic stricture. For the majority with non-erosive disease, intermittent or on-demand therapy reduces medication burden without compromising symptom control" [1].

Rebound acid hypersecretion is a real phenomenon after PPI discontinuation. A randomized study in Gastroenterology (N=120) showed that 44% of healthy volunteers developed dyspeptic symptoms after 8 weeks of PPI use followed by abrupt cessation, compared to 15% on placebo [19]. Tapering over 2-4 weeks and bridging with famotidine reduces rebound symptoms. Abrupt discontinuation after long-term use is not recommended.

Lifestyle Modifications That Complement Drug Therapy

Behavioral interventions work best as adjuncts to pharmacotherapy, not replacements. The measures with the strongest evidence include weight loss (a 2006 NEJM study of 10,545 women found a BMI reduction of 3.5 units decreased reflux symptoms by 40%) [20], head-of-bed elevation by 6-8 inches, and avoiding meals within 3 hours of lying down.

Specific food triggers vary by individual, and blanket dietary restrictions lack strong evidence. A 2006 systematic review in Archives of Internal Medicine found that only weight loss and head-of-bed elevation had consistent supporting data, while eliminating chocolate, caffeine, spicy foods, or citrus showed inconsistent results across studies [21]. The practical recommendation: patients should identify and avoid their personal triggers rather than following rigid elimination diets.

Tobacco cessation deserves specific emphasis. Smoking reduces LES pressure, decreases salivary bicarbonate (which normally neutralizes refluxed acid), and slows esophageal clearance. Quitting cigarettes reduces reflux symptoms measurably within 3-6 months.

When Reflux Requires Surgical Intervention

Anti-reflux surgery (fundoplication) is reserved for patients with confirmed GERD who respond to PPIs but prefer to discontinue medication, cannot tolerate PPIs, or have large hiatal hernias with persistent regurgitation despite adequate acid suppression. The LOTUS trial (N=554) compared laparoscopic Nissen fundoplication with esomeprazole therapy over 5 years and found equivalent remission rates (92% surgery vs. 93% medical) [22]. Surgery is not superior to optimized medical therapy for most patients.

Magnetic sphincter augmentation (LINX device) is a newer option that places a ring of titanium-encased magnetic beads around the LES. Five-year data (N=100) published in Clinical Gastroenterology and Hepatology showed 85% of patients discontinued daily PPIs, though 6% required device removal [23]. This option suits patients with moderate regurgitation and confirmed GERD on pH testing who want to stop medication without traditional fundoplication.